24-26 Feb, 2027
Grand Nikko Tokyo DaibaTokyo Adam Martin, PhDVice President, Chemistry at PYC TherapeuticsSpeaker
Profile
Dr Adam Martin is the Vice President of Chemistry at PYC Therapeutics. He leads the design and manufacture of PYC’s clinical therapeutics which utilise both PYC’s proprietary peptide platform and deep oligonucleotide capabilities. He has over 10 years’ experience in the TIDES field across roles in both academia and industry. His work at PYC has encompassed early Discovery, R&D and clinical development of new molecular entities across ophthalmology, neurology and nephrology. He has authored over 50 peer reviewed papers, has been awarded >$7M in research funding and holds several patents on TIDES-based technology.
Agenda Sessions
PYC-001 A Peptide-oligonucleotide Conjugate for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
, 8:45amView Session